World's First Patient-specific Pluripotent Stem Cell Company, Utilizing RGI`s Patient-somatic Cell Reprogramming "STEMBRID" Technology. RGI and Tokyo based JIG Inc Establish ASCLEPIUS THERAPEUTICS.
December 08, 2005 Health News(PRLEAP.COM) For Immediate Release: December 2005
Tokyo, Japan.-Chicago based RGI and Japanese Cell Therapy company JIG establish Asclepius Therapeutics, to develop and commercialize the breakthrough "Stembrid" Platform Technology, the Worlds first success in Somatic cell reprogramming technology to create genetically matched pluripotent stem cells for therapeutic applications for a range of incurable illnesses from Parkinson's and heart disease to diabetes, Cancers, and spinal injuries.
JIG will begin clinical testing on Animals for safety and efficacy in 2006 in Taiwan and India, with JIG`s established research partners. After safety tests established JIG will begin testing on Humans.
The "stembrid" technique uses existing ESCs instead of human eggs, no embryos or Clones are created or destroyed, and would solve many ethical problems. The Stembrid also offers great economical advantage over therapeutic Cloning because of the high costs and dependence of Human eggs, and enable the mass production of Pluripotent stem cells that are genetically identical to the Patients with incurable diseases and disorders. published online by Reproductive BioMedicine Online, rbmonline.com/Article/2071 November 2005. published in print -January 2006 issue
JIG Corporation was established in 1999 by CEO J. Joseph Ryan, Focused on finding cure for his 3year old bedridden Son who suffers from a devastating illness. JIG has searched for the Worlds top Stem cell scientists teams. And now have the World`s leading Stem cell therapeutic technologies In
1. Pluripotent stem cell therapeutic technology, (genetic matched)
2. Human Umbilical Cord Blood Stem cell therapy technology.
3. Bone marrow therapy technology.,
4. Blood derived Mononuclear cell technology
5. Scaffold Bio- Material.
JIG is focused on Therapeutic application of Stem cells to Cure or treat incurable illnesses.
JIG has long had a exclusive relationship to commercialize RGI technologies in Japan and Korea
RGI, the World`s leader in treating difficult infertility problems.Worlds leader and Pioneer in Pre-implantation Genetic Diagnosis, and Under the leadership of CEO Dr. Yury Verlinsky, RGI is now the World`s leading the largest Embryonic Stem cell bank with over 140 stem cell lines. RGI was the first in the World and largest bank with Diseased /Abnormal Stem cell lines for Research and Drug testing. RGI`s Stembrid technology can make Patient-specific stem cell Therapy possible without the need for cloning.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.